A cancer cell that has not been exposed to inhibitors (e.g. against mutant EGFR) could arise, particularly at an advanced stage of disease, with activating mutations in both EGFR and KRAS; but we would anticipate that other events—like decreased RAS-GTP levels---might prevent P-ERK from reaching toxic levels. This evidence concerns the gene MAPK1 and cancer.